Update
$Annovis Bio(ANVS.US$ Annovis Bio (NYSE:ANVS) said the Data and Safety Monitoring Board has issued a positive recommendation for its Phase 2/3 study of its drug buntanetap in the treatment of mild-to-moderate Alzheimer’s disease.
Annovis said the board found no drug-related Serious Adverse Events, and an Adverse Event rate of less than 5%. The dropout rate for the study was 4.7%.
The company started the study in late March 2023.
Annovis said the board found no drug-related Serious Adverse Events, and an Adverse Event rate of less than 5%. The dropout rate for the study was 4.7%.
The company started the study in late March 2023.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
